thalidomide has been researched along with Astrocytoma, Grade IV in 24 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma." | 9.20 | Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. ( Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK, 2015) |
| "The Radiation Therapy Oncology Group (RTOG) initiated the single-arm, phase II study 9806 to determine the safety and efficacy of daily thalidomide with radiation therapy in patients with newly diagnosed glioblastoma." | 9.17 | A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). ( Alexander, BM; Curran, WJ; Donahue, BA; Fine, HA; Hartford, AC; Kerlin, KJ; Mehta, MP; Richards, RS; Tremont, IW; Wang, M; Yung, WK, 2013) |
| "To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy." | 9.14 | A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. ( Barron, L; Batchelor, TT; Black, PM; Ciampa, A; David, K; Doherty, L; Drappatz, J; Kesari, S; Lafrankie, DC; Norden, A; Ostrowsky, L; Ramakrishna, N; Sceppa, C; Schiff, D; Smith, ST; Weiss, S; Wen, PY; Wong, ET; Zimmerman, J, 2009) |
| "External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone." | 9.14 | A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. ( Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK, 2010) |
| " Thalidomide, an antiangiogenic agent, may play a role in the treatment of glioblastoma multiforme (GBM)." | 9.13 | A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. ( Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW, 2008) |
| "This phase II study aimed at determining the efficacy and safety of irinotecan combined with thalidomide in adults with recurrent glioblastoma multiforme (GBM) not taking enzyme-inducing anticonvulsants (EIACs)." | 9.13 | Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. ( Colman, H; Conrad, CA; de Groot, JF; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Hsu, SH; Ictech, SE; Jackson, EF; Levin, VA; Mahankali, S; Puduvalli, VK; Ritterhouse, MG; Yung, WK, 2008) |
| "We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma." | 9.13 | Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. ( Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY, 2008) |
| "A phase II study was conducted to assess the efficacy of administering daily thalidomide concomitantly with radiation and continuing for up to 1 year following radiation in children with brain stem gliomas (BSG) or glioblastoma multiforme (GBM)." | 9.12 | Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. ( Briody, C; Chi, S; Chordas, C; Goumnerova, LC; Kieran, MW; MacDonald, T; Marcus, KJ; Packer, RJ; Poussaint, TY; Scott, RM; Turner, CD; Ullrich, N; Vajapeyam, S; Zimmerman, MA, 2007) |
| "Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)." | 9.12 | A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007) |
| " Thalidomide was well tolerated, with constipation and sedation being the major toxicities." | 9.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "For its numerous abilities including sedation, we have been using thalidomide (TH) as the 'last therapeutic option' in patients with advanced gliomas." | 7.81 | Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. ( Ackerl, M; Dieckmann, KU; Flechl, B; Hainfellner, JA; Hassler, MR; Marosi, C; Prayer, D; Preusser, M; Rössler, K; Sax, C; Woehrer, A, 2015) |
| "13-cis-retinoic acid (RA) and thalidomide have shown a synergistic anti-proliferative effect on U343 glioblastoma (GBM) cells." | 7.80 | The influence of retinoic Acid and thalidomide on the radiosensitivity of u343 glioblastoma cells. ( Herskind, C; Maier, P; Milanović, D; Schanne, DH; Wenz, F, 2014) |
| "Thalidomide was well tolerated: the most common side effects were constipation (76." | 6.71 | Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. ( Carillio, G; Fanelli, M; Gasparini, G; Gattuso, D; Morabito, A; Sarmiento, R, 2004) |
| "Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2)." | 6.71 | Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. ( Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W, 2004) |
| "Thalidomide is a well-tolerated drug that may have some activity in the treatment of recurrent glioblastoma." | 6.70 | Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. ( Bell, DR; Biggs, M; Boyle, FM; Cook, R; Levi, JA; Little, N; Marx, GM; McCowatt, S; Pavlakis, N; Wheeler, HR, 2001) |
| "Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma." | 5.20 | Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. ( Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK, 2015) |
| "The Radiation Therapy Oncology Group (RTOG) initiated the single-arm, phase II study 9806 to determine the safety and efficacy of daily thalidomide with radiation therapy in patients with newly diagnosed glioblastoma." | 5.17 | A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). ( Alexander, BM; Curran, WJ; Donahue, BA; Fine, HA; Hartford, AC; Kerlin, KJ; Mehta, MP; Richards, RS; Tremont, IW; Wang, M; Yung, WK, 2013) |
| "To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy." | 5.14 | A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. ( Barron, L; Batchelor, TT; Black, PM; Ciampa, A; David, K; Doherty, L; Drappatz, J; Kesari, S; Lafrankie, DC; Norden, A; Ostrowsky, L; Ramakrishna, N; Sceppa, C; Schiff, D; Smith, ST; Weiss, S; Wen, PY; Wong, ET; Zimmerman, J, 2009) |
| "External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone." | 5.14 | A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. ( Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK, 2010) |
| " Thalidomide, an antiangiogenic agent, may play a role in the treatment of glioblastoma multiforme (GBM)." | 5.13 | A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. ( Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW, 2008) |
| "This phase II study aimed at determining the efficacy and safety of irinotecan combined with thalidomide in adults with recurrent glioblastoma multiforme (GBM) not taking enzyme-inducing anticonvulsants (EIACs)." | 5.13 | Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. ( Colman, H; Conrad, CA; de Groot, JF; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Hsu, SH; Ictech, SE; Jackson, EF; Levin, VA; Mahankali, S; Puduvalli, VK; Ritterhouse, MG; Yung, WK, 2008) |
| "We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma." | 5.13 | Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. ( Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY, 2008) |
| "A phase II study was conducted to assess the efficacy of administering daily thalidomide concomitantly with radiation and continuing for up to 1 year following radiation in children with brain stem gliomas (BSG) or glioblastoma multiforme (GBM)." | 5.12 | Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. ( Briody, C; Chi, S; Chordas, C; Goumnerova, LC; Kieran, MW; MacDonald, T; Marcus, KJ; Packer, RJ; Poussaint, TY; Scott, RM; Turner, CD; Ullrich, N; Vajapeyam, S; Zimmerman, MA, 2007) |
| "Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)." | 5.12 | A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007) |
| " Thalidomide was well tolerated, with constipation and sedation being the major toxicities." | 5.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "For its numerous abilities including sedation, we have been using thalidomide (TH) as the 'last therapeutic option' in patients with advanced gliomas." | 3.81 | Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. ( Ackerl, M; Dieckmann, KU; Flechl, B; Hainfellner, JA; Hassler, MR; Marosi, C; Prayer, D; Preusser, M; Rössler, K; Sax, C; Woehrer, A, 2015) |
| "13-cis-retinoic acid (RA) and thalidomide have shown a synergistic anti-proliferative effect on U343 glioblastoma (GBM) cells." | 3.80 | The influence of retinoic Acid and thalidomide on the radiosensitivity of u343 glioblastoma cells. ( Herskind, C; Maier, P; Milanović, D; Schanne, DH; Wenz, F, 2014) |
| " Although thalidomide-induced dermatologic disorders rarely were reported before thalidomide was administered to patients positive for the human immunodeficiency virus, hypersensitivity reactions including rash are the agent's major dose-limiting toxicities in this population." | 3.70 | Thalidomide-induced toxic epidermal necrolysis. ( Horowitz, SB; Stirling, AL, 1999) |
| "Thalidomide was well tolerated: the most common side effects were constipation (76." | 2.71 | Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. ( Carillio, G; Fanelli, M; Gasparini, G; Gattuso, D; Morabito, A; Sarmiento, R, 2004) |
| "Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2)." | 2.71 | Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. ( Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W, 2004) |
| "Thalidomide is a well-tolerated drug that may have some activity in the treatment of recurrent glioblastoma." | 2.70 | Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. ( Bell, DR; Biggs, M; Boyle, FM; Cook, R; Levi, JA; Little, N; Marx, GM; McCowatt, S; Pavlakis, N; Wheeler, HR, 2001) |
| " Additionally, we investigated a potential enhancement of the antitumoral action of thalidomide when combined with a low dose of the antineoplastic carmustine." | 1.31 | Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma. ( Arrieta, O; Guevara, P; Rembao, D; Rivera, E; Sotelo, J; Tamariz, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 14 (58.33) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, Z | 1 |
| Wang, B | 1 |
| Liu, H | 1 |
| Shi, L | 1 |
| Guo, G | 1 |
| Gong, K | 1 |
| Puliyappadamba, VT | 1 |
| Panchani, N | 1 |
| Pan, E | 1 |
| Mukherjee, B | 1 |
| Damanwalla, Z | 1 |
| Bharia, S | 1 |
| Hatanpaa, KJ | 1 |
| Gerber, DE | 1 |
| Mickey, BE | 1 |
| Patel, TR | 1 |
| Sarkaria, JN | 1 |
| Zhao, D | 1 |
| Burma, S | 1 |
| Habib, AA | 1 |
| Milanović, D | 2 |
| Maier, P | 2 |
| Schanne, DH | 1 |
| Wenz, F | 2 |
| Herskind, C | 2 |
| Penas-Prado, M | 1 |
| Hess, KR | 3 |
| Fisch, MJ | 1 |
| Lagrone, LW | 1 |
| Groves, MD | 4 |
| Levin, VA | 3 |
| De Groot, JF | 2 |
| Puduvalli, VK | 3 |
| Colman, H | 3 |
| Volas-Redd, G | 1 |
| Giglio, P | 3 |
| Conrad, CA | 3 |
| Salacz, ME | 1 |
| Floyd, JD | 1 |
| Loghin, ME | 1 |
| Hsu, SH | 2 |
| Gonzalez, J | 2 |
| Chang, EL | 1 |
| Woo, SY | 1 |
| Mahajan, A | 2 |
| Aldape, KD | 1 |
| Yung, WK | 6 |
| Gilbert, MR | 4 |
| Hassler, MR | 1 |
| Sax, C | 1 |
| Flechl, B | 1 |
| Ackerl, M | 1 |
| Preusser, M | 1 |
| Hainfellner, JA | 1 |
| Woehrer, A | 1 |
| Dieckmann, KU | 1 |
| Rössler, K | 1 |
| Prayer, D | 1 |
| Marosi, C | 1 |
| Iwamoto, FM | 1 |
| Lassman, AB | 1 |
| Wang, Y | 1 |
| Xing, D | 1 |
| Zhao, M | 1 |
| Wang, J | 1 |
| Yang, Y | 1 |
| Drappatz, J | 2 |
| Wong, ET | 1 |
| Schiff, D | 3 |
| Kesari, S | 2 |
| Batchelor, TT | 2 |
| Doherty, L | 2 |
| Lafrankie, DC | 1 |
| Ramakrishna, N | 2 |
| Weiss, S | 1 |
| Smith, ST | 1 |
| Ciampa, A | 2 |
| Zimmerman, J | 1 |
| Ostrowsky, L | 1 |
| David, K | 1 |
| Norden, A | 1 |
| Barron, L | 1 |
| Sceppa, C | 1 |
| Black, PM | 3 |
| Wen, PY | 4 |
| Fadul, CE | 1 |
| Kingman, LS | 1 |
| Meyer, LP | 1 |
| Cole, BF | 1 |
| Eskey, CJ | 1 |
| Rhodes, CH | 1 |
| Roberts, DW | 1 |
| Newton, HB | 1 |
| Pipas, JM | 1 |
| Aguilera, DG | 1 |
| Tomita, T | 1 |
| Rajaram, V | 1 |
| Fangusaro, J | 1 |
| Katz, BZ | 1 |
| Shulman, S | 1 |
| Goldman, S | 1 |
| Hunter, K | 1 |
| Hess, K | 1 |
| Chang, E | 1 |
| Puduvalli, V | 1 |
| Conrad, C | 1 |
| Levin, V | 1 |
| Woo, S | 1 |
| de Groot, J | 1 |
| Alexander, BM | 1 |
| Wang, M | 1 |
| Fine, HA | 2 |
| Donahue, BA | 1 |
| Tremont, IW | 1 |
| Richards, RS | 1 |
| Kerlin, KJ | 1 |
| Hartford, AC | 1 |
| Curran, WJ | 1 |
| Mehta, MP | 1 |
| Morabito, A | 1 |
| Fanelli, M | 1 |
| Carillio, G | 1 |
| Gattuso, D | 1 |
| Sarmiento, R | 1 |
| Gasparini, G | 1 |
| Phuphanich, S | 1 |
| Chang, SM | 2 |
| Lamborn, KR | 2 |
| Malec, M | 1 |
| Larson, D | 1 |
| Wara, W | 1 |
| Sneed, P | 1 |
| Rabbitt, J | 1 |
| Page, M | 1 |
| Nicholas, MK | 1 |
| Prados, MD | 2 |
| Turner, CD | 1 |
| Chi, S | 1 |
| Marcus, KJ | 1 |
| MacDonald, T | 1 |
| Packer, RJ | 1 |
| Poussaint, TY | 1 |
| Vajapeyam, S | 1 |
| Ullrich, N | 1 |
| Goumnerova, LC | 1 |
| Scott, RM | 1 |
| Briody, C | 1 |
| Chordas, C | 1 |
| Zimmerman, MA | 1 |
| Kieran, MW | 1 |
| Tremont-Lukats, IW | 1 |
| Liu, TJ | 1 |
| Peterson, P | 1 |
| Cloughesy, TF | 1 |
| Greenberg, H | 1 |
| Abrey, LE | 1 |
| DeAngelis, LM | 1 |
| Lohr, F | 1 |
| Mahankali, S | 1 |
| Jackson, EF | 1 |
| Ritterhouse, MG | 1 |
| Ictech, SE | 1 |
| Henson, JW | 1 |
| Muzikansky, A | 1 |
| Gigas, DC | 1 |
| Longtine, JA | 1 |
| Ligon, KL | 1 |
| Weaver, S | 1 |
| Laforme, A | 1 |
| Folkman, J | 1 |
| Kieran, M | 1 |
| Horowitz, SB | 1 |
| Stirling, AL | 1 |
| Figg, WD | 1 |
| Jaeckle, K | 1 |
| Kyritsis, AP | 1 |
| Loeffler, JS | 1 |
| Kaplan, R | 1 |
| Pluda, JM | 1 |
| Marx, GM | 1 |
| Pavlakis, N | 1 |
| McCowatt, S | 1 |
| Boyle, FM | 1 |
| Levi, JA | 1 |
| Bell, DR | 1 |
| Cook, R | 1 |
| Biggs, M | 1 |
| Little, N | 1 |
| Wheeler, HR | 1 |
| Arrieta, O | 1 |
| Guevara, P | 1 |
| Tamariz, J | 1 |
| Rembao, D | 1 |
| Rivera, E | 1 |
| Sotelo, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme[NCT00112502] | Phase 2 | 178 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Phase II Study Of Thalidomide And CPT-11 (IRINOTECAN) Following Radiotherapy For Glioblastoma Multiforme[NCT00039468] | Phase 2 | 26 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme[NCT00006358] | Phase 2 | 44 participants (Actual) | Interventional | 2000-06-13 | Completed | ||
| Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting[NCT00047294] | Phase 2 | 0 participants | Interventional | 2001-04-30 | Completed | ||
| A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas[NCT00047879] | Phase 2 | 7 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Celecoxib versus not Celecoxib analysis: We compared the median OS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Celecoxib: Arm III, Arm V, Arm VI and Arm VIII | 20.2 |
| No Celecoxib: Arm I, Arm II, Arm IV and Arm VII | 17.1 |
Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median OS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Doublet (2 Agents): Arm II, Arm III and Arm IV | 17.0 |
| Triplet (3 Agents): Arm V, Arm VI and Arm VII | 20.1 |
Isotretinoin versus not Isotretinoin analysis: We compared the median OS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Isotretinoin: Arm IV, Arm V, Arm VII and ARM VIII | 17.1 |
| No Isotretinoin: Arm I, Arm II, Arm III and ARM VI | 19.9 |
Thalidomide versus not Thalidomide analysis: We compared the median OS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII | 18.3 |
| No Thalidomide: Arm I, Arm III, Arm IV and Arm V | 17.4 |
Celecoxib versus not Celecoxib analysis: We compared the median PFS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Celecoxib: Arm III, Arm V, Arm VI and Arm VIII | 8.3 |
| No Celecoxib: Arm I, Arm II, Arm IV and Arm VII | 7.4 |
Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median PFS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Doublet (2 Agents): Arm II, Arm III and Arm IV | 8.3 |
| Triplet (3 Agents): Arm V, Arm VI and Arm VII | 8.2 |
Isotretinoin versus not Isotretinoin analysis: We compared the median PFS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Isotretinoin: Arm IV, Arm V, Arm VII and Arm VIII | 6.6 |
| No Isotretinoin: Arm I, Arm II, Arm III and Arm VI | 9.1 |
Thalidomide versus not Thalidomide analysis: Comparison of median PFS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up, up to one year (12 study cycles).
| Intervention | months (Median) |
|---|---|
| Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII | 7.6 |
| No Thalidomide: Arm I, Arm III, Arm IV and Arm V | 8.7 |
Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Arm I: TMZ | 10.5 |
| Arm II: TMZ + Thalidomide | 7.7 |
| Arm III: TMZ + Celecoxib | 13.4 |
| Arm IV: TMZ + Isotretinoin | 6.5 |
| Arm V: TMZ + Isotretinoin + Celecoxib | 11.6 |
| Arm VI: TMZ + Thalidomide + Celecoxib | 7.9 |
| Arm VII: TMZ + Thalidomide + Isotretinoin | 6.2 |
| Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib | 5.8 |
Overall Survival (OS) was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Arm I: TMZ | 21.2 |
| Arm II: TMZ + Thalidomide | 17.4 |
| Arm III: TMZ + Celecoxib | 18.1 |
| Arm IV: TMZ + Isotretinoin | 11.7 |
| Arm V: TMZ + Isotretinoin + Celecoxib | 23.1 |
| Arm VI: TMZ + Thalidomide + Celecoxib | 20.2 |
| Arm VII: TMZ + Thalidomide + Isotretinoin | 17.9 |
| Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib | 18.5 |
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00047879)
Timeframe: 4 months
| Intervention | Participants (Number) |
|---|---|
| Glioblastoma Multiforme Stratum | 4 |
| Anaplastic Glioma Stratum | 2 |
1 review available for thalidomide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Topics: Angiogenesis Inhibitors; Bevacizumab; Glioblastoma; Humans; Recurrence; Salvage Therapy; Thalidomide | 2016 |
13 trials available for thalidomide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cele | 2015 |
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dose-Response Relati | 2009 |
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Ne | 2008 |
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Celecoxib; Chemotherapy, Adjuvant; Combined Modality | 2010 |
A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Brain Neoplasms; Chemoradiotherapy; Female; Follow-Up St | 2013 |
Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Constipation; Disease Progression; Female; Glioblastoma; Heada | 2004 |
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2004 |
Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.
Topics: Adolescent; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Combined Modality Therapy; Disease | 2007 |
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2007 |
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease- | 2008 |
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2008 |
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality T | 2000 |
Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Endothelial Growth Factors | 2001 |
10 other studies available for thalidomide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
TNF Inhibitor Pomalidomide Sensitizes Glioblastoma Cells to EGFR Inhibition.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; ErbB Rec | 2020 |
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell | 2019 |
The influence of retinoic Acid and thalidomide on the radiosensitivity of u343 glioblastoma cells.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dose-Response Relat | 2014 |
Thalidomide as palliative treatment in patients with advanced secondary glioblastoma.
Topics: Adult; Antineoplastic Agents; Female; Glioblastoma; Glioma; Humans; Male; Palliative Care; Retrospec | 2015 |
Factorial clinical trials: a new approach to phase II neuro-oncology studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Isotr | 2015 |
Glioblastoma multiforme in a patient with chronic granulomatous disease treated with subtotal resection, radiation, and thalidomide: case report of a long-term survivor.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Diagnosis, Differential; Female; | 2009 |
Recurrent multicentric glioblastoma multiforme responds to thalidomide and chemotherapy.
Topics: Adult; Antineoplastic Agents; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Thalidomide; T | 2002 |
Inhibition of 13-cis retinoic acid-induced gene expression of homeobox B7 by thalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferat | 2007 |
Thalidomide-induced toxic epidermal necrolysis.
Topics: Angiogenesis Inhibitors; Female; Glioblastoma; Humans; Hypersensitivity; Middle Aged; Stevens-Johnso | 1999 |
Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell D | 2002 |